NEW YORK, NY / ACCESSWIRE / September 17, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Oatly Group AB (NASDAQ:OTLY)
CONTACT JAKUBOWITZ ABOUT OTLY:
https://claimyourloss.com/securities/oatly-group-ab-loss-submission-form/?id=19664&from=1
Class Period : May 20, 2021 - July 15, 2021
Lead Plaintiff Deadline : September 24, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) Oatly overinflated its gross margins, revenue, capital expenditure, and market share financial metrics; (b) the Company overstated its sustainability practices and impact; (c) the Company exaggerated its growth in China; and (c) as a result of the foregoing, Oatly's statements about its operations, business, and prospects were misleading during the Class Period.

AdaptHealth Corp. f/k/a DFB Healthcare Acquisitions Corp. (NASDAQ:AHCO)
CONTACT JAKUBOWITZ ABOUT AHCO:
https://claimyourloss.com/securities/adapthealth-corp-f-k-a-dfb-healthcare-acquisitions-corp-loss-submission-form/?id=19664&from=1
Class Period : November 11, 2019 - July 16, 2021
Lead Plaintiff Deadline : September 27, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) AdaptHealth had misrepresented its organic growth trajectory by retroactively inflating past organic growth numbers without disclosing the changes, in violation of Securities and Exchange Commission regulations; (ii) accordingly, the Company had materially overstated its financial prospects; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Cassava Sciences, Inc. (NASDAQ:SAVA)
CONTACT JAKUBOWITZ ABOUT SAVA:
https://claimyourloss.com/securities/cassava-sciences-inc-loss-submission-form/?id=19664&from=1
Class Period : February 2, 2021 - August 24, 2021
Lead Plaintiff Deadline : October 26, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) the quality and integrity of the scientific data supporting Cassava's claims for simufilam's, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava's claims for simufilam's efficacy were biased; and (c) as a result of the foregoing, Defendants' positive statements during the Class Period about the Company's business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and/or lacked a reasonable basis.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law